188 related articles for article (PubMed ID: 12835119)
21. Effects of acute and chronic administration of dizocilpine on the pharmacological responses to U-50,488H and brain and spinal cord kappa-opioid receptors in the rat.
Bhargava HN; Matwyshyn GA; Gudehithlu KP
Pharmacology; 1995 Nov; 51(5):323-30. PubMed ID: 8584584
[TBL] [Abstract][Full Text] [Related]
22. Molecular mechanisms of agonist-induced desensitization of the cloned mouse kappa opioid receptor.
Raynor K; Kong H; Hines J; Kong G; Benovic J; Yasuda K; Bell GI; Reisine T
J Pharmacol Exp Ther; 1994 Sep; 270(3):1381-6. PubMed ID: 7932192
[TBL] [Abstract][Full Text] [Related]
23. Involvement of kappa-opioid receptor mechanisms in the calcitonin-induced potentiation of opioid effects at the hypothalamus-pituitary-adrenocortical axis.
Milanés MV; Vargas ML; Martín MI
Eur J Pharmacol; 1994 Dec; 271(1):103-9. PubMed ID: 7698193
[TBL] [Abstract][Full Text] [Related]
24. The site of anti-arthritic action of the kappa-opioid, U-50, 488H, in adjuvant arthritis: importance of local administration.
Wilson JL; Nayanar V; Walker JS
Br J Pharmacol; 1996 Aug; 118(7):1754-60. PubMed ID: 8842441
[TBL] [Abstract][Full Text] [Related]
25. Antinociceptive actions of dexmedetomidine and the kappa-opioid agonist U-50,488H against noxious thermal, mechanical and inflammatory stimuli.
Idänpään-Heikkilä JJ; Kalso EA; Seppälä T
J Pharmacol Exp Ther; 1994 Dec; 271(3):1306-13. PubMed ID: 7996439
[TBL] [Abstract][Full Text] [Related]
26. Effects of chronic U50,488H treatment on binding and mechanical responses of the rat hearts.
Xia Q; Sheng JZ; Tai KK; Wong TM
J Pharmacol Exp Ther; 1994 Feb; 268(2):930-4. PubMed ID: 8114007
[TBL] [Abstract][Full Text] [Related]
27. Kappa opioid receptor agonists suppress absence seizures in WAG/Rij rats.
Przewłocka B; Lasoń W; Machelska H; van Luijtelaar G; Coenen A; Przewłocki R
Neurosci Lett; 1995 Feb; 186(2-3):131-4. PubMed ID: 7777181
[TBL] [Abstract][Full Text] [Related]
28. Kappa opioid antagonist effects of the novel kappa antagonist 5'-guanidinonaltrindole (GNTI) in an assay of schedule-controlled behavior in rhesus monkeys.
Negus SS; Mello NK; Linsenmayer DC; Jones RM; Portoghese PS
Psychopharmacology (Berl); 2002 Oct; 163(3-4):412-9. PubMed ID: 12373442
[TBL] [Abstract][Full Text] [Related]
29. Inhibitory effect of a selective kappa receptor agonist, U-50, 488H, on methamphetamine-elicited ipsilateral circling behavior in rats with unilateral nigral lesions.
Ohno M; Yamamoto T; Ueki S
Psychopharmacology (Berl); 1989; 97(2):219-21. PubMed ID: 2543013
[TBL] [Abstract][Full Text] [Related]
30. Effects of rat brain kappa 1- and kappa 2-opioid receptors after chronic treatment with non-peptide kappa-agonists.
McConnaughey MM; Zhai QZ; Ingenito AJ
J Pharm Pharmacol; 1998 Oct; 50(10):1121-5. PubMed ID: 9821658
[TBL] [Abstract][Full Text] [Related]
31. Heterologous mu-opioid receptor adaptation by repeated stimulation of kappa-opioid receptor: up-regulation of G-protein activation and antinociception.
Narita M; Khotib J; Suzuki M; Ozaki S; Yajima Y; Suzuki T
J Neurochem; 2003 Jun; 85(5):1171-9. PubMed ID: 12753076
[TBL] [Abstract][Full Text] [Related]
32. Behavioral Pharmacology of Novel Kappa Opioid Receptor Antagonists in Rats.
Page S; Mavrikaki MM; Lintz T; Puttick D; Roberts E; Rosen H; Carroll FI; Carlezon WA; Chartoff EH
Int J Neuropsychopharmacol; 2019 Nov; 22(11):735-745. PubMed ID: 31613314
[TBL] [Abstract][Full Text] [Related]
33. Differential effects of micro-opioid, delta-opioid and kappa-opioid receptor agonists on dopamine receptor agonist-induced climbing behavior in mice.
Ito S; Mori T; Sawaguchi T
Behav Pharmacol; 2006 Dec; 17(8):691-701. PubMed ID: 17110795
[TBL] [Abstract][Full Text] [Related]
34. Differential antagonism of bremazocine- and U69,593-induced antinociception by quadazocine: further functional evidence of opioid kappa receptor multiplicity in the mouse.
Horan PJ; de Costa BR; Rice K; Haaseth RC; Hruby VJ; Porreca F
J Pharmacol Exp Ther; 1993 Aug; 266(2):926-33. PubMed ID: 8394923
[TBL] [Abstract][Full Text] [Related]
35. The kappa opioid agonist U50,488 potentiates 6-hydroxydopamine-induced neurotoxicity on dopaminergic neurons.
Marin C; Bové J; Serrats J; Cortés R; Mengod G; Tolosa E
Exp Neurol; 2005 Jan; 191(1):41-52. PubMed ID: 15589511
[TBL] [Abstract][Full Text] [Related]
36. Serotonergic mechanisms involved in calcitonin potentiation of kappa-opioid receptor-mediated effects on adrenal secretion.
Ormazábal MJ; Milanés MV; Martín MI
Eur J Pharmacol; 1997 Dec; 340(1):81-7. PubMed ID: 9527510
[TBL] [Abstract][Full Text] [Related]
37. Comparative effects of selective kappa-opioid receptor agonists on dopamine levels in the dorsal caudate of freely moving rats.
Zaratin P; Clarke GD
Eur J Pharmacol; 1994 Oct; 264(2):151-6. PubMed ID: 7851477
[TBL] [Abstract][Full Text] [Related]
38. Pharmacological characterization of ATPM [(-)-3-aminothiazolo[5,4-b]-N-cyclopropylmethylmorphinan hydrochloride], a novel mixed kappa-agonist and mu-agonist/-antagonist that attenuates morphine antinociceptive tolerance and heroin self-administration behavior.
Wang YJ; Tao YM; Li FY; Wang YH; Xu XJ; Chen J; Cao YL; Chi ZQ; Neumeyer JL; Zhang A; Liu JG
J Pharmacol Exp Ther; 2009 Apr; 329(1):306-13. PubMed ID: 19136637
[TBL] [Abstract][Full Text] [Related]
39. Effects of the kappa-opioid receptor agonist U-50,488 on morphine-induced place preference conditioning in the developing rat.
Bolanos CA; Garmsen GM; Clair MA; McDougall SA
Eur J Pharmacol; 1996 Dec; 317(1):1-8. PubMed ID: 8982712
[TBL] [Abstract][Full Text] [Related]
40. Nonspecific effects of the selective kappa-opioid receptor agonist U-50,488H on dopamine uptake and release in PC12 cells.
Chudapongse N; Kim SY; Kramer RE; Ho IK
J Pharmacol Sci; 2003 Nov; 93(3):372-5. PubMed ID: 14646257
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
